Health
Compassionate use of tocilizumab in severe SARS-CoV2 pneumonia – MD Linx
MDLinx original journal summary on Pneumonia, Infectious Disease from International Journal of Infectious Diseases
In the treatment of severe SARS-CoV-2 pneumonia (SSP), tocilizumab has been used with the aim to relieve the cytokine release syndrome (CRS)-induced acute respiratory distress syndrome (ARDS). Researchers here investigated the patients in whom it might benefit the most. Tocilizumab on a compassionate-use basis was provided to hospitalized patients with SSP (excluding intensive care and intubated cases) who required oxygen support to have a saturation > 93%. They studied a total of 207 patients and…
-
General13 hours agoChina and Philippines trade blame over latest South China Sea clash
-
General23 hours agoThree maps that show the scale of the NSW flood disaster
-
General13 hours agoSmall plane crashes into San Diego neighbourhood, setting homes and vehicles on fire
-
Noosa News22 hours agoConfusion over licensing and access to hunting grounds under WA’s strict gun laws